Key facts
- This page summarizes David I. Sandoval's Form 4 filing for MAXCYTE, INC. (MXCT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Mar 2025, 20:49.
David I. Sandoval - 14 Mar 2025 Form 4 Insider Report for MAXCYTE, INC. (MXCT)
- Reporting relationship
- GENERAL COUNSEL
- Issuer ticker
- MXCT
- Reported as of
- 14 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Mar 2025, 20:49:42 UTC
- Prior SEC filing
- 14 Jan 2025
- Next SEC filing
- 20 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Sandoval
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David I. Sandoval filed Form 4 for MAXCYTE, INC. (MXCT) on 18 Mar 2025.
Change
- Previous filing in this sequence was filed on 14 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MXCT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +23,125
- Change %
- +56%
- Price
- $0.000000
- Shares after
- 64,572
- Date
- 14 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MXCT
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +92,500
- Change %
- Price
- $0.000000
- Shares after
- 92,500
- Date
- 14 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 92,500
- Exercise price
- $3.29
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Twenty-five percent (25%) of the RSUs shall vest on March 14, 2026, and the remainder shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Footnote F2
Twenty-five percent (25%) of the shares underlying this option shall vest on March 14, 2026, and the remainder shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.